The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Atazanavir Krka

150 milligram(s) Capsule, hard

Krka d.d., Novo mestoEU/1/19/1353/001

Main Information

Trade NameAtazanavir Krka
Active SubstancesAtazanavir sulfate
Strength150 milligram(s)
Dosage FormCapsule, hard
Licence HolderKrka d.d., Novo mesto
Licence NumberEU/1/19/1353/001

Group Information

ATC CodeJ05AE Protease inhibitors
J05AE08 atazanavir

Status

Authorised/WithdrawnAuthorised
Licence Issued25/03/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back